

Microenvironmental variables must influence intrinsic phenotypic parameters of cancer stem cells to affect tumourigenicity

Jacob G Scott^{1,2*}, Anita Hjelmeland³, Prakash Chinnaiyan⁴, Alexander R. A. Anderson¹ & David Basanta^{1*}

¹ Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

² Centre for Mathematical Biology, Mathematical Institute, University of Oxford, Oxford, UK

³ Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA

⁴ Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Abstract

Since the discovery of tumour initiating cells (TICs) in solid tumours, studies focussing on their role in cancer initiation and progression have abounded. The biological interrogation of these cells continues to yield volumes of information on their pro-tumourigenic behaviour, but actionable generalised conclusions have been scarce. Further, new information suggesting a dependence of tumour composition and growth on the microenvironment has yet to be studied theoretically. To address this point, we created a hybrid, discrete/continuous computational cellular automaton model of a generalised stem-cell driven tissue with a simple microenvironment. Using the model we explored the phenotypic traits inherent to the tumour initiating cells and the effect of the microenvironment on tissue growth. We identify the regions in phenotype parameter space where TICs are able to cause a disruption in homeostasis, leading to tissue overgrowth and tumour maintenance. As our parameters and model are non-specific, they could apply to any tissue TIC and do not assume specific genetic mutations. Targeting these phenotypic traits could represent a generalizable therapeutic strategy across cancer types. Further, we find that the microenvironmental variable does not strongly effect the outcomes, suggesting a need for direct feedback from the microenvironment onto stem-cell behaviour in future modelling endeavours.

*Corresponding authors: jacob.g.scott@gmail.com, david@CancerEvo.org

34 **Author Summary:**

35 In this paper, we present a mathematical/computational model of a tumour growing accord-
36 ing to the canonical cancer stem-cell hypothesis with a simplified microenvironment. We
37 explore the parameters of this model and find good agreement between our model and other
38 theoretical models in terms of the intrinsic cellular parameters, which are difficult to study
39 biologically. We find, however, disagreement between novel biological data and our model
40 in terms of the microenvironmental changes. We conclude that future theoretical models
41 of stem-cell driven tumours must include specific feedback from the microenvironment onto
42 the individual cellular behavior. Further, we identify several cell intrinsic parameters which
43 govern loss of homeostasis into a state of uncontrolled growth.

44 Introduction

45 Heterogeneity among cancer cells within the same patient contributes to tumour growth and
46 evolution. A subpopulation of tumour cells, called Tumour Initiating cells (TICs), or cancer
47 stem cells, has recently been shown to be highly tumourigenic in xenograft models and have
48 some properties of normal stem cells. Although controversial, there is a growing body of
49 evidence that TICs can drive tumour growth and recurrence in many cancers, including, but
50 not limited to, brain [1], breast [2] and colon [3]. These tumour types can be broadly classed
51 as hierarchical tumours as they have been posited to follow some of the same hierarchical
52 organisation as healthy stem-cell (SC) driven tissues. In these hierarchical tumors, TICs can
53 differentiate to produce non-TIC cancer cells or self-renew to promote tumor maintenance.
54 As TICs have been demonstrated to be resistant to a wide variety of therapies including
55 radiation and chemotherapy, the TIC hypothesis has important implications for patient
56 treatments [4]. Specifically, the effect of current strategies on the tumor cell hierarchy should
57 be defined, and TIC specific therapies are likely to provide strong benefit for cancer patients.

58 In a simplified view of the tumour cell hierarchy, TICs can divide symmetrically or
59 asymmetrically to, respectively, produce two TIC daughters or a TIC daughter and a more
60 differentiated progeny [5, 6]. More differentiated TIC progeny which still have the capability
61 of cell division and are similar to transient amplifying cells (TACs) in the standard stem-
62 cell model and are capable of several rounds of their own symmetric division before the
63 amplified population then differentiates into terminally differentiated cells (TDs) which are
64 incapable of further division. This mode of division and differentiation, which we will call
65 the Hierarchical Model (HM) is schematized in Fig 1.

66 In the HM, there are a number of cellular behaviours that govern the system. In this
67 study, we choose to study three: the rate of symmetric versus asymmetric division of the stem
68 cells (α), the number of ‘rounds’ of amplification that transient amplifying cell can undergo




Figure 1: Cartoon representing the hierarchical model of stem-cell driven tissues. In this formulation, each stem can undergo two types of division, either symmetric (with probability α) or asymmetric (with probability $1 - \alpha$). Each subsequently generated transient amplifying cell (TAC) can then undergo a certain number (β) of round of amplification before differentiating into a terminally differentiated cell (TD) which will live for a certain amount of time before dying (γ timesteps). It is these three parameters, which we assume are intrinsic to a given stem cell, which we explore in this paper.

69 before terminal differentiation (β), and the relative lifespan of a terminally differentiated
70 cell (γ). While it is a simplification of reality to study only these three parameters and
71 leave out others (for example: differing proliferation rates for the different cell types [7]
72 or the differing metabolic demands of stem vs. non-stem cells [8]) rigorous quantification
73 of these parameters has been extremely difficult to pin down experimentally and so the
74 majority of the work to describe them has been *in silico*. Most germane to the loss of
75 homeostasis is the work by Enderling et al. [9] which showed the changes to the size of
76 a mutated tissue (tumour) as they varied the number of rounds of amplification of TACs.

77 Other recent work attempting to quantify the ratio of symmetric to asymmetric division in
78 putative glioma stem cells was presented by Lathia et al. [10], who showed that this ratio can
79 change depending on the medium, suggesting yet another method by which a tissue can lose
80 or maintain homeostasis: in reaction to microenvironmental change. A critical limitation
81 of *in vivo* lineage tracing performed to date is an inability to determine the impact of
82 microenvironmental heterogeneity on TIC symmetric division.

83 While the HM appears to be quite straight forward, there is growing evidence of complex-
84 ity to be further incorporated into the model. There are likely to be differences in the extent
85 of TIC maintenance or the ability of tumour cells to move toward a TIC state. TICs appear
86 to reside in distinct niches suggesting there may be differences in the biology of these cells,
87 but defining differences in TICs is limited by cell isolation and tumour initiation methods.
88 Prospective isolation of TICs relies on surface markers, including CD133, CD151 and CD24
89 which can be transient in nature [11], due to modulation by the tumour microenvironment
90 or methods of isolation [12]. Characterisation of these sorted cells then requires functional
91 assays including *in vitro* and *in vivo* limiting dilution assay as well as determination of
92 expression of stem cell factors including Oct4, Nanog and others [13].

93 As the importance of TICs becomes more and more evident as it pertains to aspects of
94 tumour progression like heterogeneity [14], treatment resistance [15, 16], recurrence [17] and
95 metastasis [18], the need for generalizable therapeutic strategies based on conserved motifs
96 in these cells grows. We therefore aim to understand how the phenotypic traits discussed
97 earlier (asymmetric division rate, allowed rounds of transient amplification and lifespan of
98 terminally differentiated cells) and microenvironmental changes (modelled as differences in
99 oxygen supply) effect resultant tissue growth characteristics.

100 To this end, we present a minimal spatial, hybrid-discrete/continuous mathematical
101 model of a hierarchical SC-driven tissue architecture which we have used to explore the
102 intrinsic, phenotypic, factors involved in the growth of TIC-driven tumours. We consider

103 parameters that involve the rates of division of the cells involved in the hierarchical cascade
104 as well as micro-environmental factors including space and competition between cell types
105 for oxygen. We present results suggesting that there are discrete regimes in the intrinsic
106 cellular parameter space which allow for disparate growth characteristics of the resulting
107 tumours, specifically: TICs that are incapable of forming tumours, TICs that are capable of
108 forming only small colonies (spheres), and TICs that are capable of forming fully invasive
109 tumours *in silico*, just as we see diversity in biological experiments (Fig 4).

110 **Methods**

111 Our model is based on a hybrid, discrete-continuous cellular automaton model (HCA) of
112 a hierarchically structured tissue. HCA models have been used to study cancer progres-
113 sion and evolutionary dynamics since they can integrate biological parameters and produce
114 predictions affecting different spatial and time scales [14, 19, 20, 21, 22, 23]. As shown in
115 figure 2C, cells are modelled in a discrete fashion on a 500x500 2-D lattice. This comprises
116 approximately $1cm^2$ where we assume a cell diameter of 20 micrometers [24]. The domain
117 has periodic boundary conditions but the simulations are stopped when a cell reaches one
118 of the boundaries. Every time step, cells are iterated in a random fashion as to avoid any
119 bias in the way that cells are chosen. Figure 2A shows that, although all cells are assumed
120 to have the same size and shape, they can only be one of three different phenotypes: TICs
121 capable of infinite divisions, TACs which are capable of division into two daughters for a
122 certain number (β) of generations, and TDs which cannot divide but live and consume nu-
123 trients for a specified lifetime (γ). Modes of division for TICs include asymmetric division
124 (with probability $1 - \alpha$), which is division into one TIC daughter and one TAC daughter
125 and symmetric division, which is division into two TIC daughters (probability α).

126 The continuous portion of this model is made of up the distribution and consumption

127 of nutrients (in this case modelled only as oxygen). Vessels, which are modelled as point
128 sources and take up one lattice point ($V_{i,j}$ in Equation 1), are placed randomly throughout
129 the grid at the initiation of a given simulation, in a specified density (Θ). Each of these vessels
130 supplies oxygen at a constant rate (λ) which then diffuses into the surrounding tissue. The
131 diffusion speed/distance is described by Equation 1, where $O(x, y, t)$ is the concentration of
132 oxygen at a given time (t), and place (x, y) , D_O is the diffusion coefficient of oxygen, λ is the
133 rate of oxygen production from a blood vessel, μ_s , μ_p , and μ_t are the rates at which TIC,
134 TAC and TD cells consume oxygen. The difference in time scales that govern the diffusion of
135 nutrients and that at which cells operate is managed by updating the continuous part of the
136 model 100 times per time step. During each update the oxygen tension in a given grid point
137 is updated with the values of the surrounding cells using a von Neumann neighbourhood
138 modulated by the diffusionrate (D_O).

$$\frac{\partial O(x, y, t)}{\partial t} = D_O \nabla^2 O(x, y, t) + \lambda V_{x,y} - \mu_S S_{x,y} - \mu_P P_{x,y} - \mu_T T_{x,y} \quad (1)$$

139 Any simulation performed by this model can be characterised by the parameters found
140 in table 1. The most relevant parameters for the question we are trying to address are the
141 following:

- 142 • Symmetric/asymmetric division rate of stem cells (α)
- 143 • Vascular density of the tissue (Θ)
- 144 • Number of allowed divisions of TACs (β)
- 145 • Lifespan of TDs (γ)

146 In each case, as can be seen in figure 2, a simulation is seeded with one TIC with a given set
147 of intrinsic parameters (α, β, γ) governing its and its progeny's behaviour, which is placed in
148 the centre of the computational domain. The domain is initialised with as many randomly




Figure 2: Computational model description. (A) The model includes three different cell types: stem, progenitor and differentiated. All cell types interact with the microenvironment in the form of oxygen tension. (B) The behaviour of each cell type is captured by a flowchart. The last segment with discontinuous arrows represents behaviour that is specific to the stem cells. (C) The cells are represented as agents inhabiting points in a grid in a 2D space with 500x500 grid points. Stem cells are represented as red points, progenitor as green and fully differentiated as blue. The vasculature is represented as oxygen source points in black.

149 placed oxygen source points (vasculature) as described by the vascular density parameter
 150 (Θ).

151 Results

152 A systematic parameter exploration of the three key parameters relating to vascularisation
 153 of the domain, symmetric vs. asymmetric division (α) and progenitor division potential (β)
 154 was performed. We also explored the parameter determining the lifespan of differentiated
 155 cells (γ) and found that the only impact of longer lifespans is an increase in the amount
 156 of time before the simulations reach a steady state, but does not change the qualitative
 157 nature of the results. These results are summarised in Figure 4. Each of the three panels
 158 represents the results for a different degree of vascularisation (0.01, 0.05 and 0.1). A density

Parameter	value
D_o (Oxygen diffusion)	0.001728
λ (Rate of Oxygen production)	1
μ_s, μ_p, μ_T	0.0001
α (Ratio of SC symmetric division)	0.1, 0.3, 0.5
β (TAC proliferative potential)	1,5,10,11,12,13,14,15,16,17,18,19,20,50,70,100
γ (Differentiated cell lifespan)	1
Θ (Vascularisation)	0.001, 0.01, 0.05, 0.1, 0.5

Figure 3: Model parameters.

159 of vascularisation of 0.05 would mean 12,500 oxygen sources in the domain. To determine
160 the diffusion coefficient, we used the estimate of approximately 70 micrometers of effective
161 oxygenation [25]. Each plot shows the total tissue size after 50,000 time steps as we change
162 the proliferative potential of progenitor cells. Each of the lines shows a different ratio of
163 symmetric vs asymmetric divisions. These results show that all these three parameters have
164 a critical range where homeostasis is disrupted (tumourigenesis).

165 Figure 4 shows examples of the typical results produced by this model. Although the
166 proliferation rates of all the cells remain the same, due to space constraints and the differences
167 in α , the population of TICs does not grow at the same rate as the non-stem population.
168 Figure 4A shows an example of an unviable tissue (parameters: $\Theta = 0.001$, $\alpha = 0.3$, $\beta = 50$
169 and $\gamma = 1$ day) where the vascularisation does not support the potential tissue size of that
170 TIC, resulting in an area of hypoxia affecting the region that contains the TIC. That leads to
171 the death of the stem cell and, eventually, the rest of the cells in the tissue. Figure 4B shows
172 a case of slightly increased symmetric division, resulting in a dynamic homeostasis where




Figure 4: Three different examples of simulations resulting from the computational model. Each simulation represents one of the typical outcomes. Each begins with a single TIC seeded in the middle of the computational domain and the same vascular density. In each situation the phenotype parameters are slightly different, resulting in (A) An unsustainable tissue (parameters: $\Theta = 0.001$, $\alpha = 0.3$, $\beta = 50$ and $\gamma = 1$ day), (B) A homeostatic tissue where the balance of stem cell self renewal and progenitor proliferation leads to a tissue whose overall size remains relatively constant over time, possibly representing a dormant tumor (parameters: $\Theta = 0.05$, $\alpha = 0.3$, $\beta = 15$ and $\gamma = 1$ day) and, (C) Neoplastic-like tissue where the tissue overgrows the computational domain (parameters: $\Theta = 0.05$, $\alpha = 0.3$, $\beta = 5$ and $\gamma = 1$ day). (D) Bright field images of clonal CD133+ patient derived glioblastoma cell lines cultured in Neurobasal supplemented with EGF, FGF and B27, exhibiting similar phenotypic variability to the computation model outcomes.

173 cell birth and death is balanced so that tissue size remains relatively constant - which could
 174 represent the enigmatic dormant phase [9]. Finally, figure 4C shows an example where the
 175 system never achieves true homeostasis. In this case α is slightly higher when compared with
 176 the previous example, suggesting a critical value at which overgrowth occurs. Over time,
 177 the number of TICs increases, allowing for the ‘tumour phenotype’: unconstrained growth.
 178 Although this leads to areas of hypoxia, cells survive in the periphery of the blood vessels
 179 and keep growing until they take over the entire domain.

180 Unsurprisingly, the higher the vascularisation of the domain the greater the tissue size

181 it can support. Past a certain threshold, however, the difference becomes negligible and
 182 more remarkably, the qualitative dynamics are unchanged by any change in the microenvi-
 183 ronment. The same effect is evident in the other two parameters, the ratio of symmetric vs
 184 asymmetric division (α) of TICs and the proliferative potential of TACs (β). Regardless of
 185 the vascularisation, disruption of homeostasis only occurs when the proliferative potential
 186 of TACs (β) is below a maximum value of about 15. For values of symmetric division (α)
 187 above 0.3, the values for β in which this overgrowth occurs becomes even more restrictive
 188 with a range of approximately 10-15.

189 Interestingly, we observed a conserved decrease in overall tissue size for the highest value
 190 of symmetric division, $\alpha = 0.5$, when the progenitor cells were allowed only 5 divisions
 191 ($\beta = 5$). We believe this phenomenon represents a situation where the tissue is not able to
 192 grow to its potential as the stem cells themselves occupy too much space, and never allow
 193 the progenitors to contribute as much as they could to the overall population. This is a
 194 supposition however, and deserves closer study.




Figure 5: Size of tissues vs. progenitor proliferative potential achieved by simulations using different levels of vascularisation and ratios of symmetric vs asymmetric divisions. Lines represent averages for each of the three realisations in each scenario. (Left) Low vascularisation density of 0.01 (Centre) Normal vascularisation density of 0.05 (Right) High vascularisation density of 0.1. In each of these cases, the maximum tissue size will depend on the right combination of α and β .

195 Of note as well: in no simulation did we observe the ‘tumour phenotype’ for a value
196 of $\alpha < 0.3$, suggesting something akin to a ‘phenotypic tumour suppressor’ function for
197 this parameter. As observed biologically [10], this ratio is highly susceptible to changes in
198 microenvironment, suggesting an extension of this minimal model to include the microenvi-
199 ronmental factors measured in that study. How to incorporate the changes observed in that
200 study into a mechanistic HCA model however, is not trivial, and we reserve it for a future
201 extension of this work.

202 Discussion

203 In this paper we have presented a simple computational model of the HM of a TIC-driven
204 tissue. Our results show that there are distinct regions in parameter space (that directly
205 correlate to the intrinsic TIC phenotype space) that encode vastly different behaviour in the
206 tissue (or tumour) arising from the TIC in question. These parameters represent different
207 TIC phenotypes, and therefore do not represent any specific genetic mutation. In this way,
208 we hope to generalise the intrinsic alterations which a TIC could undergo much in the same
209 way that the ‘hallmarks of cancer’ have generalised non TIC-specific alterations [26]: our
210 end goal being the identification of treatment strategies to target these phenotypes to slow
211 or stop the progression of TIC-driven cancers.

212 Because of the difficulties in understanding TIC specific traits *in vivo*, the biological data
213 to support these conclusions remains sparse. There have been some carefully undertaken
214 *in vitro* experiments on single TICs in glioblastoma, a highly invasive and malignant brain
215 tumour, which suggest that TIC specific division behaviour (α in our model) is variable
216 and changes based on environmental cues [10]. Further work has shown that the other
217 microenvironmental cues, such as acidity [13] and hypoxia [27, 28, 29, 30, 31, 32, 33] can
218 also alter the prevalence of the stem phenotype by utilising functional markers of stemness,

219 but the mechanism for this increase is, as of yet, imperfectly understood.

220 Of note, our simulations do not show a significant TIC population dependence on vascular
221 density (Θ), a surrogate for hypoxia, or a change in stem composition (see supplemental
222 spreadsheet), suggesting a flaw in the model. To rectify this, future iterations of this model
223 should include direct feedback onto the cellular parameters from the microenvironment. We
224 aim to parameterize this dependence by specific *in vitro* experiments designed to *quantify*
225 *this effect*, rather than just elucidate its existence. Other future developments of this model
226 should take into consideration the emerging body of work suggesting that the proportion of
227 TICs within a tumour is directly affected by therapy and not just physiologic growth factor
228 controls [34]. There is now evidence in several cancers to suggest that radiation increases the
229 size of the TIC pool. Specifically, in breast cancer, it has been shown that radiation therapy
230 induces non-stem cancer cells to de-differentiate into TICs [35]. Further, experimental studies
231 have shown radiation increases the TIC pool in glioblastoma [36], which has often been
232 attributed to radiation resistance [15] alone. A new study by Gao et al. [37], however, has
233 shown *in silico* and *in vitro* that radiation can effect the symmetric to asymmetric division
234 ratio (our intrinsic parameter α), yielding further clues about the mechanism of this TIC
235 pool expansion.

236 This behaviour, dedifferentiation due to treatment related microenvironmental factors,
237 has not yet been considered in any spatial theoretical models. Dedifferentiation due to
238 ‘niche’ specific factors was studied by Sottoriva et al. [23], whose findings were similar to
239 ours: that the microenvironment made no significant change to the overall tumour growth
240 dynamics. Beyond this single spatial study, the concept of SC dedifferentiation is gaining
241 more and more attention in conceptual theoretical treatments [38] and has been modelled
242 with a deterministic ordinary differential equation system for a well-mixed population of
243 cells [39].

244 We, as well as others, find that the HM of tissue growth does not completely capture all

245 the necessary dynamics that characterise cancer growth - but there is still a great deal of
246 understanding to be gained from studying this formalism. To this end, we have performed
247 a study of the factors related to TICs driving this dynamic and have identified several key
248 factors which promote increased growth of the resultant tumour. In the same way that
249 Hanahan and Weinberg [26] have simplified the myriad (epi)genetic alterations which a
250 tumour can undergo into the ‘hallmarks of cancer’ we seek to distill the traits of TICs in the
251 same way. Specifically, we have found that the number of allowed divisions of TACs exhibits
252 bounds outside of which tumour growth is unsustainable. This finding has been corroborated
253 independently by recent work from Morton and colleagues [40]. Further, there is a specific
254 balance of symmetric to asymmetric division which keeps tumours from overgrowing; almost
255 acting as a phenotypic ‘tumour suppressor’. Indeed, changes in this ratio have been recently
256 hypothesized to underlie the increasing stem pool in glioblastoma after irradiation [37], and
257 could also represent a key to understanding tumour dormancy [9].

258 In summary, we have presented a minimal spatial Hybrid Cellular Automaton model
259 of the HM of a TIC-driven tissue in which we have explored generalised TIC phenotypic
260 traits and have identified several key cellular parameters which influence the overall tissue
261 behaviour. While our model does capture a number of salient phenotypic characteristics of
262 TICs that seem to be conserved, it fails to capture the recently observed changes in stem
263 fraction secondary to microenvironmental perturbations. This is an indication that any com-
264 putational model of a stem-hierarchical tissue, or tumour, built from this point on must not
265 only include the physical microenvironment, but also feedback from the microenvironment
266 onto the specific cellular parameters encoded in the HM.

267 Therefore, this endeavour has identified the crucial point that the microenvironment
268 must effect the behaviour of the cells within the HM, and also several conserved phenotypic
269 ‘hallmarks’, which could be the result of any number of (epi)genetic alterations or microen-
270 vironmental perturbations. By focussing on phenotype instead of genotype, and identifying

271 the key points of the HM of stem-cell driven tumour growth, we have provided a begin-
272 ning to identification of the therapeutic targets to a more tractable set as compared to the
273 panoply of possible mutations encoding similar traits. Only with this sort of distillation of
274 the biological complexity inherent to cancer initiation (and indeed progression) can we hope
275 to make progress against this disease.

276 References

- 277 [1] Sheila K Singh, Cynthia Hawkins, Ian D Clarke, Jeremy A Squire, Jane Bayani,
278 Takuichiro Hide, R Mark Henkelman, Michael D Cusimano, and Peter B Dirks. Identifi-
279 cation of human brain tumour initiating cells. *Nature*, 432(7015):396–401, Nov 2004.
- 280 [2] Muhammad Al-Hajj, Max S Wicha, Adalberto Benito-Hernandez, Sean J Morrison, and
281 Michael F Clarke. Prospective identification of tumorigenic breast cancer cells. *Proc*
282 *Natl Acad Sci U S A*, 100(7):3983–8, Apr 2003.
- 283 [3] Arnout G Schepers, Hugo J Snippert, Daniel E Stange, Maaike van den Born, Johan H
284 van Es, Marc van de Wetering, and Hans Clevers. Lineage tracing reveals lgr5+ stem
285 cell activity in mouse intestinal adenomas. *Science*, 337(6095):730–5, Aug 2012.
- 286 [4] Maximilian Diehn, Robert W Cho, and Michael F Clarke. Therapeutic implications of
287 the cancer stem cell hypothesis. *Semin Radiat Oncol*, 19(2):78–86, Apr 2009.
- 288 [5] Sean J Morrison and Judith Kimble. Asymmetric and symmetric stem-cell divisions in
289 development and cancer. *Nature*, 441(7097):1068–74, Jun 2006.
- 290 [6] T Reya, S J Morrison, M F Clarke, and I L Weissman. Stem cells, cancer, and cancer
291 stem cells. *Nature*, 414(6859):105–11, Nov 2001.
- 292 [7] Benjamin Werner, David Dingli, Tom Lenaerts, Jorge M Pacheco, and Arne Traulsen.
293 Dynamics of mutant cells in hierarchical organized tissues. *PLoS Comput Biol*,
294 7(12):e1002290, Dec 2011.
- 295 [8] Erina Vlashi, Chann Lagadec, Laurent Vergnes, Tomoo Matsutani, Kenta Masui, Maria
296 Poulou, Ruxandra Popescu, Lorenza Della Donna, Patrick Evers, Carmen Dekmezian,
297 Karen Reue, Heather Christofk, Paul S Mischel, and Frank Pajonk. Metabolic state of
298 glioma stem cells and nontumorigenic cells. *Proc Natl Acad Sci U S A*, 108(38):16062–7,
299 Sep 2011.

- 300 [9] Heiko Enderling, Alexander R A Anderson, Mark A J Chaplain, Afshin Beheshti, Lynn
301 Hlatky, and Philip Hahnfeldt. Paradoxical dependencies of tumor dormancy and pro-
302 gression on basic cell kinetics. Cancer Res, 69(22):8814–21, Nov 2009.
- 303 [10] J D Lathia, M Hitomi, J Gallagher, S P Gadani, J Adkins, A VasANJI, L Liu, C E
304 Eyler, J M Heddlestone, Q Wu, S Minhas, A Soeda, D J Hoepfner, R Ravin, R D G
305 McKay, R E McLendon, D Corbeil, A Chenn, A B Hjelmeland, D M Park, and J N
306 Rich. Distribution of cd133 reveals glioma stem cells self-renew through symmetric and
307 asymmetric cell divisions. Cell Death Dis, 2:e200, 2011.
- 308 [11] Piyush B Gupta, Christine M Fillmore, Guozhi Jiang, Sagi D Shapira, Kai Tao, Char-
309 lotte Kuperwasser, and Eric S Lander. Stochastic state transitions give rise to pheno-
310 typic equilibrium in populations of cancer cells. Cell, 146(4):633–44, Aug 2011.
- 311 [12] Paola Brescia, Cristina Richichi, and Giuliana Pelicci. Current strategies for identifica-
312 tion of glioma stem cells: adequate or unsatisfactory? J Oncol, 2012:376894, 2012.
- 313 [13] A B Hjelmeland, Q Wu, J M Heddlestone, G S Choudhary, J MacSwords, J D Lathia,
314 R McLendon, D Lindner, A Sloan, and J N Rich. Acidic stress promotes a glioma stem
315 cell phenotype. Cell Death Differ, 18(5):829–40, May 2011.
- 316 [14] Andrea Sottoriva, Joost J C Verhoeff, Tijana Borovski, Shannon K McWeeney, Lev
317 Naumov, Jan Paul Medema, Peter M A Sloot, and Louis Vermeulen. Cancer stem cell
318 tumor model reveals invasive morphology and increased phenotypical heterogeneity.
319 Cancer Res, 70(1):46–56, Jan 2010.
- 320 [15] Shideng Bao, Qiulian Wu, Roger E McLendon, Yueling Hao, Qing Shi, Anita B Hjelme-
321 land, Mark W Dewhirst, Darell D Bigner, and Jeremy N Rich. Glioma stem cells
322 promote radioresistance by preferential activation of the dna damage response. Nature,
323 444(7120):756–60, Dec 2006.
- 324 [16] Jian Chen, Yanjiao Li, Tzong-Shiue Yu, Renée M McKay, Dennis K Burns, Steven G
325 Kernie, and Luis F Parada. A restricted cell population propagates glioblastoma growth
326 after chemotherapy. Nature, 488(7412):522–6, Aug 2012.
- 327 [17] David Dingli and Franziska Michor. Successful therapy must eradicate cancer stem cells.
328 Stem Cells, 24(12):2603–10, Dec 2006.
- 329 [18] Roberta Pang, Wai Lun Law, Andrew C Y Chu, Jensen T Poon, Colin S C Lam, Ariel
330 K M Chow, Lui Ng, Leonard W H Cheung, Xiao R Lan, Hui Y Lan, Victoria P Y Tan,
331 Thomas C Yau, Ronnie T Poon, and Benjamin C Y Wong. A subpopulation of cd26+
332 cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell,
333 6(6):603–15, Jun 2010.
- 334 [19] Alexander R A Anderson. A hybrid mathematical model of solid tumour invasion: the
335 importance of cell adhesion. Math Med Biol, 22(2):163–86, Jun 2005.

- 336 [20] Alexander R A Anderson, Mohamed Hassanein, Kevin M Branch, Jenny Lu, Nic-
337 hole A Lobdell, Julie Maier, David Basanta, Brandy Weidow, Archana Narasanna,
338 Carlos L Arteaga, Albert B Reynolds, Vito Quaranta, Lourdes Estrada, and Alissa M
339 Weaver. Microenvironmental independence associated with tumor progression. Cancer
340 Res, 69(22):8797–806, Nov 2009.
- 341 [21] Alexander R A Anderson, Alissa M Weaver, Peter T Cummings, and Vito Quaranta.
342 Tumor morphology and phenotypic evolution driven by selective pressure from the mi-
343 croenvironment. Cell, 127(5):905–15, Dec 2006.
- 344 [22] David Basanta, Douglas W Strand, Ralf B Lukner, Omar E Franco, David E Cliffl,
345 Gustavo E Ayala, Simon W Hayward, and Alexander R A Anderson. The role of
346 transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer
347 progression: an integrative approach. Cancer Res, 69(17):7111–20, Sep 2009.
- 348 [23] Andrea Sottoriva, Peter M A Slood, Jan Paul Medema, and Louis Vermeulen. Exploring
349 cancer stem cell niche directed tumor growth. Cell Cycle, 9(8):1472–9, Apr 2010.
- 350 [24] M M Melicow. The three steps to cancer: a new concept of cancerigenesis. J Theor
351 Biol, 94(2):471–511, Jan 1982.
- 352 [25] Eric J Hall and Amato J Giaccia. Radiobiology for the radiologist. Wolters Kluwer
353 Health/Lippincott Williams and Wilkins, Philadelphia, 7th ed edition, 2012.
- 354 [26] Douglas Hanahan and Robert A Weinberg. Hallmarks of cancer: the next generation.
355 Cell, 144(5):646–74, Mar 2011.
- 356 [27] John M Heddleston, Zhizhong Li, Roger E McLendon, Anita B Hjelmeland, and
357 Jeremy N Rich. The hypoxic microenvironment maintains glioblastoma stem cells and
358 promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle, 8(20):3274–
359 84, Oct 2009.
- 360 [28] Zhizhong Li, Shideng Bao, Qiulian Wu, Hui Wang, Christine Eyler, Sith Sathornsume-
361 tee, Qing Shi, Yiting Cao, Justin Lathia, Roger E McLendon, Anita B Hjelmeland, and
362 Jeremy N Rich. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem
363 cells. Cancer Cell, 15(6):501–13, Jun 2009.
- 364 [29] Sascha Seidel, Boyan K Garvalov, Valtteri Wirta, Louise von Stechow, Anne Schänzer,
365 Konstantinos Meletis, Marietta Wolter, Daniel Sommerlad, Anne-Theres Henze, Monica
366 Nistér, Guido Reifenberger, Joakim Lundberg, Jonas Frisé, and Till Acker. A hypoxic
367 niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain,
368 133(Pt 4):983–95, Apr 2010.
- 369 [30] Eli E Bar, Alex Lin, Vasiliki Mahairaki, William Matsui, and Charles G Eberhart.
370 Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in
371 glioblastoma neurospheres. Am J Pathol, 177(3):1491–502, Sep 2010.

- 372 [31] A Soeda, M Park, D Lee, A Mintz, A Androutsellis-Theotokis, R D McKay, J Engh,
373 T Iwama, T Kunisada, A B Kassam, I F Pollack, and D M Park. Hypoxia pro-
374 motes expansion of the cd133-positive glioma stem cells through activation of hif-1alpha.
375 Oncogene, 28(45):3949–59, Nov 2009.
- 376 [32] Julie Mathieu, Zhan Zhang, Wenyu Zhou, Amy J Wang, John M Heddleston, Claudia
377 M A Pinna, Alexis Hubaud, Bradford Stadler, Michael Choi, Merav Bar, Muneesh
378 Tewari, Alvin Liu, Robert Vessella, Robert Rostomily, Donald Born, Marshall Horwitz,
379 Carol Ware, C Anthony Blau, Michele A Cleary, Jeremy N Rich, and Hannele Ruohola-
380 Baker. Hif induces human embryonic stem cell markers in cancer cells. Cancer Res,
381 71(13):4640–52, Jul 2011.
- 382 [33] Jesper Kolenda, Stine Skov Jensen, Charlotte Aaberg-Jessen, Karina Christensen, Claus
383 Andersen, Nils Brünner, and Bjarne Winther Kristensen. Effects of hypoxia on ex-
384 pression of a panel of stem cell and chemoresistance markers in glioblastoma-derived
385 spheroids. J Neurooncol, 103(1):43–58, May 2011.
- 386 [34] Louis Vermeulen, Felipe De Sousa E Melo, Maartje van der Heijden, Kate Cameron,
387 Joan H de Jong, Tijana Borovski, Jurriaan B Tuynman, Matilde Todaro, Christian
388 Merz, Hans Rodermond, Martin R Sprick, Kristel Kemper, Dick J Richel, Giorgio
389 Stassi, and Jan Paul Medema. Wnt activity defines colon cancer stem cells and is
390 regulated by the microenvironment. Nat Cell Biol, 12(5):468–76, May 2010.
- 391 [35] Chann Lagadec, Erina Vlashi, Lorenza Della Donna, Carmen Dekmezian, and Frank
392 Pajonk. Radiation-induced reprogramming of breast cancer cells. Stem Cells, 30(5):833–
393 44, May 2012.
- 394 [36] Kaoru Tamura, Masaru Aoyagi, Hiroaki Wakimoto, Noboru Ando, Tadashi Nariai,
395 Masaaki Yamamoto, and Kikuo Ohno. Accumulation of cd133-positive glioma cells
396 after high-dose irradiation by gamma knife surgery plus external beam radiation. J
397 Neurosurg, 113(2):310–8, Aug 2010.
- 398 [37] Xuefeng Gao, J Tyson McDonald, Lynn Hlatky, and Heiko Enderling. Acute and frac-
399 tionated irradiation differentially modulate glioma stem cell division kinetics. Cancer
400 Res, 73(5):1481–90, Mar 2013.
- 401 [38] Louis Vermeulen, Felipe de Sousa e Melo, Dick J Richel, and Jan Paul Medema. The
402 developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol,
403 13(2):e83–9, Feb 2012.
- 404 [39] Kevin Leder, Eric C Holland, and Franziska Michor. The therapeutic implications of
405 plasticity of the cancer stem cell phenotype. PLoS One, 5(12):e14366, 2010.
- 406 [40] Charles I Morton, Lynn Hlatky, Philip Hahnfeldt, and Heiko Enderling. Non-stem
407 cancer cell kinetics modulate solid tumor progression. Theor Biol Med Model, 8:48,
408 2011.